恩替卡韦联合苦参素治疗慢性乙型肝炎的有效性研究

发布时间：2018-06-17 16:35

  本文选题：恩替卡韦 + 苦参素　； 参考：《中华医院感染学杂志》2017年07期

【摘要】：目的探讨恩替卡韦联合苦参素治疗慢性乙型肝炎的有效性研究,为慢性乙型肝炎的治疗提供参考。方法选取2014年6月-2015年6月医院收治的100例慢性乙型肝炎患者,分为观察组与对照组,各50例;对照组仅服用恩替卡韦治疗,观察组加用苦参素口服,比较两组患者临床指标。结果两组治疗后胆红素(TBil)、门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、HBV-DNA水平均与治疗前比较下降,观察组较对照组下降幅度明显,差异有统计学意义(P0.05);两组HA、LN、IV-C、PCⅢ水平治疗后均与治疗前比较下降,观察组较对照组下降幅度明显(P0.05)。结论恩替卡韦联合苦参素治疗慢性乙型肝炎能明显提高病毒血清标志物转阴率及改善肝纤维化状态,提高临床治疗效果。
[Abstract]:Objective to investigate the efficacy of entecavir combined with matrine in the treatment of chronic hepatitis B (CHB). Methods from June 2014 to June 2015, 100 patients with chronic hepatitis B were divided into the observation group and the control group, 50 cases in each group, the control group was treated only with entecavir, the observation group was treated with matrine orally, and the clinical indexes of the two groups were compared. Results after treatment, the levels of bilirubin T bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (alanine aminotransferase) in the two groups were all decreased compared with those before treatment, and the levels of HBV-DNA in the observation group were significantly lower than those in the control group. The difference was statistically significant (P 0.05), the level of Hal LNV IV-CU PC 鈪，

本文编号：2031686